Benchmark Reaffirms “Buy” Rating for Humacyte (NASDAQ:HUMA)

Benchmark restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Thursday morning,Benzinga reports.

Several other analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte currently has an average rating of “Buy” and a consensus price target of $13.71.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $3.40 on Thursday. The business’s 50 day simple moving average is $4.36 and its two-hundred day simple moving average is $4.95. The firm has a market cap of $427.92 million, a P/E ratio of -2.54 and a beta of 1.30. Humacyte has a 52-week low of $2.81 and a 52-week high of $9.97.

Institutional Trading of Humacyte

A number of institutional investors and hedge funds have recently modified their holdings of HUMA. China Universal Asset Management Co. Ltd. increased its position in shares of Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after acquiring an additional 8,965 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new stake in shares of Humacyte during the third quarter valued at approximately $75,000. Victory Capital Management Inc. increased its position in shares of Humacyte by 551.6% during the third quarter. Victory Capital Management Inc. now owns 76,896 shares of the company’s stock valued at $418,000 after acquiring an additional 65,095 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in shares of Humacyte during the third quarter valued at approximately $712,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Humacyte during the third quarter valued at approximately $232,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.